PL360909A1 - Pochodne ftalazynonowe - Google Patents
Pochodne ftalazynonoweInfo
- Publication number
- PL360909A1 PL360909A1 PL01360909A PL36090901A PL360909A1 PL 360909 A1 PL360909 A1 PL 360909A1 PL 01360909 A PL01360909 A PL 01360909A PL 36090901 A PL36090901 A PL 36090901A PL 360909 A1 PL360909 A1 PL 360909A1
- Authority
- PL
- Poland
- Prior art keywords
- phthalazinone derivatives
- phthalazinone
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0026505.8A GB0026505D0 (en) | 2000-10-30 | 2000-10-30 | Phthalazinone derivatives |
US27506601P | 2001-03-12 | 2001-03-12 | |
PCT/GB2001/004729 WO2002036576A1 (en) | 2000-10-30 | 2001-10-25 | Phthalazinone derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
PL360909A1 true PL360909A1 (pl) | 2004-09-20 |
PL223343B1 PL223343B1 (pl) | 2016-10-31 |
Family
ID=26245211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL360909A PL223343B1 (pl) | 2000-10-30 | 2001-10-25 | Zastosowanie związku, kompozycja farmaceutyczna zawierająca związek oraz pochodne ftalazynonowe |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1330442B1 (pl) |
JP (1) | JP2009149643A (pl) |
KR (1) | KR100804564B1 (pl) |
CN (1) | CN100400518C (pl) |
AU (2) | AU2001295789B2 (pl) |
BR (1) | BR0115062A (pl) |
CA (1) | CA2423279C (pl) |
CY (1) | CY1111380T1 (pl) |
EA (1) | EA006300B1 (pl) |
GB (1) | GB2384776C (pl) |
HK (1) | HK1056880A1 (pl) |
HU (1) | HU228960B1 (pl) |
IL (2) | IL155645A0 (pl) |
MX (1) | MXPA03003218A (pl) |
NO (1) | NO325637B1 (pl) |
NZ (1) | NZ525138A (pl) |
PL (1) | PL223343B1 (pl) |
WO (1) | WO2002036576A1 (pl) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7196085B2 (en) | 2002-04-30 | 2007-03-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
CA2517629C (en) * | 2003-03-12 | 2011-07-12 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
TW200505441A (en) * | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
WO2004098528A2 (en) | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Pyrazole-amine compounds useful as kinase inhibitors |
GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
CN1905864B (zh) * | 2003-12-01 | 2011-04-06 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
CN102107008B (zh) | 2003-12-01 | 2013-04-03 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
EA014955B1 (ru) * | 2004-06-30 | 2011-04-29 | Янссен Фармацевтика Н. В. | Производные фталазина в качестве ингибиторов parp |
GB0419072D0 (en) * | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
CA2577191A1 (en) * | 2004-08-26 | 2006-03-02 | Kudos Pharmaceuticals Limited | 4-heteroarylmethyl substituted phthalazinone derivatives |
GB0428111D0 (en) * | 2004-12-22 | 2005-01-26 | Kudos Pharm Ltd | Pthalazinone derivatives |
GB0521373D0 (en) * | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
WO2007138355A1 (en) | 2006-05-31 | 2007-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
GB0716532D0 (en) | 2007-08-24 | 2007-10-03 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
AU2008299721A1 (en) | 2007-09-14 | 2009-03-19 | Astrazeneca Ab | Phthalazinone derivatives |
KR101598231B1 (ko) | 2007-10-17 | 2016-02-26 | 쿠도스 파마슈티칼스 리미티드 | 4-[3-(4-시클로프로판카르보닐-피페라진-1-카르보닐)-4-플루오로-벤질]-2h-프탈라진-1-온 |
MX2010005070A (es) | 2007-11-15 | 2010-05-24 | Angeletti P Ist Richerche Bio | Derivados de piridazinona como inhibidores de parp. |
UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
HUE030800T2 (en) | 2008-10-07 | 2017-05-29 | Astrazeneca Uk Ltd | Pharmaceutical Form No. 514 |
KR101033492B1 (ko) * | 2009-01-22 | 2011-05-12 | 김기산 | 현수막 게시대 |
WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
EP2598491B1 (en) | 2010-07-27 | 2015-09-02 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors |
CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
CN102485721B (zh) * | 2010-12-03 | 2015-12-09 | 曹亚 | 取代的2,3-二氮杂萘酮化合物及其用途 |
EP3925962A1 (en) | 2011-05-31 | 2021-12-22 | Rakovina Therapeutics Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerase |
CN102344425B (zh) * | 2011-07-26 | 2014-04-09 | 兰州大学 | 一种合成含三氟甲基呋喃化合物的方法 |
CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
CN102633732B (zh) * | 2012-03-08 | 2014-07-30 | 江苏先声药物研究有限公司 | 一类酞嗪酮衍生物及其应用 |
JP6159388B2 (ja) * | 2012-03-28 | 2017-07-05 | ニューロポア セラピーズ,インコーポレイティド | タンパク質凝集の阻害剤としてのフェニル−尿素及びフェニル−カルバメート誘導体 |
GEP201706691B (en) | 2012-12-31 | 2017-06-26 | Cadila Healthcare Ltd | Substituted phthalazin-1 (2h)-one derivatives as selecti- ve inhibitors of poly (adp-ribose) polymerase-1 |
ES2684776T3 (es) | 2013-01-18 | 2018-10-04 | Bristol-Myers Squibb Company | Ftalazinonas e isoquinolinonas como inhibidores de ROCK |
BR112015023328A2 (pt) | 2013-03-13 | 2017-07-18 | Flatley Discovery Lab | compostos de piridazinona e métodos para o tratamento de fibrose cística |
EP3013804B1 (en) * | 2013-06-24 | 2017-02-01 | Merck Patent GmbH | Phthalazine derivatives |
KR101670126B1 (ko) | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
GB201317609D0 (en) | 2013-10-04 | 2013-11-20 | Cancer Rec Tech Ltd | Inhibitor compounds |
US9902702B2 (en) | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
US10202361B2 (en) | 2014-08-29 | 2019-02-12 | Fmc Corporation | Pyridazinones as herbicides |
GB201505658D0 (en) | 2015-04-01 | 2015-05-13 | Cancer Rec Tech Ltd | Inhibitor compounds |
CN106146492A (zh) * | 2015-04-17 | 2016-11-23 | 上海汇伦生命科技有限公司 | 杂环并咪唑类化合物、其药物组合物及其制备方法和用途 |
WO2016187620A2 (en) | 2015-05-21 | 2016-11-24 | The Regents Of The University Of California | Anti-cancer compounds |
WO2017013593A1 (en) | 2015-07-22 | 2017-01-26 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
CN108138177B9 (zh) | 2015-07-23 | 2021-08-13 | 法国居里学院 | Dbait分子与PARP抑制剂的组合用于治疗癌症的用途 |
WO2017029601A1 (en) | 2015-08-17 | 2017-02-23 | Lupin Limited | Heteroaryl derivatives as parp inhibitors |
GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
IL263917B (en) | 2016-06-24 | 2022-07-01 | Univ California | Pthalazine derivatives as parp1, parp2 and/or tubulin suppressors for use in cancer therapy |
GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
CN107955001A (zh) | 2016-10-14 | 2018-04-24 | 上海汇伦生命科技有限公司 | 抗肿瘤杂环并咪唑类化合物的药用盐 |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
CN108358850B (zh) * | 2018-02-11 | 2021-01-26 | 中国药科大学 | PARP-1和Tankyrase1/2多靶点抑制剂、其制法及用途 |
US20200407720A1 (en) | 2018-03-13 | 2020-12-31 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
GB201913030D0 (en) | 2019-09-10 | 2019-10-23 | Francis Crick Institute Ltd | Treatment of hr deficient cancer |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
AU2020444056A1 (en) | 2020-04-21 | 2022-11-17 | Idience Co., Ltd. | Crystalline forms of phthalazinone compound |
WO2021220120A1 (en) | 2020-04-28 | 2021-11-04 | Rhizen Pharmaceuticals Ag | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
EP4153180A1 (en) | 2020-05-07 | 2023-03-29 | Astrazeneca AB | Combination therapy for treating cancer |
WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
WO2022170952A1 (zh) * | 2021-02-09 | 2022-08-18 | 苏州阿尔脉生物科技有限公司 | 一种作为sos1抑制剂的多环哒嗪酮类衍生物、其制备方法及用途 |
WO2022215034A1 (en) | 2021-04-08 | 2022-10-13 | Rhizen Pharmaceuticals Ag | Inhibitors of poly(adp-ribose) polymerase |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3274185A (en) * | 1963-10-08 | 1966-09-20 | S E Massengill Company | Phthalazine derivatives |
GB8610018D0 (en) * | 1986-04-24 | 1986-05-29 | Fujisawa Pharmaceutical Co | Phthalazine derivatives |
DE68920798T2 (de) * | 1988-08-19 | 1995-05-18 | Warner Lambert Co | Substituierte Dihydroisochinolinone und verwandte Verbindungen als Verstärker der letalen Effekte von Bestrahlung und bestimmten Chemotherapeutika; ausgewählte Verbindungen, Analoga und Verfahren. |
DE19630250C1 (de) * | 1996-07-26 | 1997-08-28 | Krupp Vdm Gmbh | Vollmetallischer Oxidationskatalysator |
CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
US5888529A (en) * | 1997-03-28 | 1999-03-30 | The Regents Of The University Of California | Ileus treatment method |
AU3076700A (en) * | 1999-01-26 | 2000-08-18 | Ono Pharmaceutical Co. Ltd. | 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient |
GB0026505D0 (en) * | 2000-10-30 | 2000-12-13 | Kudos Pharm Ltd | Phthalazinone derivatives |
-
2001
- 2001-10-25 GB GB0309190A patent/GB2384776C/en not_active Expired - Lifetime
- 2001-10-25 CA CA2423279A patent/CA2423279C/en not_active Expired - Lifetime
- 2001-10-25 AU AU2001295789A patent/AU2001295789B2/en active Active
- 2001-10-25 AU AU9578901A patent/AU9578901A/xx active Pending
- 2001-10-25 WO PCT/GB2001/004729 patent/WO2002036576A1/en active IP Right Grant
- 2001-10-25 NZ NZ525138A patent/NZ525138A/en not_active IP Right Cessation
- 2001-10-25 EA EA200300531A patent/EA006300B1/ru not_active IP Right Cessation
- 2001-10-25 BR BR0115062-6A patent/BR0115062A/pt not_active Application Discontinuation
- 2001-10-25 EP EP01976521A patent/EP1330442B1/en not_active Expired - Lifetime
- 2001-10-25 IL IL15564501A patent/IL155645A0/xx active IP Right Grant
- 2001-10-25 PL PL360909A patent/PL223343B1/pl unknown
- 2001-10-25 KR KR1020037005963A patent/KR100804564B1/ko active Protection Beyond IP Right Term
- 2001-10-25 CN CNB018183573A patent/CN100400518C/zh not_active Expired - Lifetime
- 2001-10-25 MX MXPA03003218A patent/MXPA03003218A/es active IP Right Grant
- 2001-10-25 HU HU0301269A patent/HU228960B1/hu unknown
-
2003
- 2003-04-02 NO NO20031498A patent/NO325637B1/no not_active IP Right Cessation
- 2003-04-29 IL IL155645A patent/IL155645A/en unknown
- 2003-12-19 HK HK03109260.1A patent/HK1056880A1/xx not_active IP Right Cessation
-
2008
- 2008-12-17 JP JP2008320616A patent/JP2009149643A/ja active Pending
-
2011
- 2011-04-05 CY CY20111100363T patent/CY1111380T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EA200300531A1 (ru) | 2003-10-30 |
AU2001295789B2 (en) | 2006-05-11 |
MXPA03003218A (es) | 2004-12-03 |
CA2423279A1 (en) | 2002-05-10 |
GB2384776A (en) | 2003-08-06 |
HK1056880A1 (en) | 2004-03-05 |
NO325637B1 (no) | 2008-06-30 |
JP2009149643A (ja) | 2009-07-09 |
HUP0301269A3 (en) | 2004-03-29 |
KR100804564B1 (ko) | 2008-02-20 |
IL155645A0 (en) | 2003-11-23 |
BR0115062A (pt) | 2004-02-17 |
CN1473154A (zh) | 2004-02-04 |
CN100400518C (zh) | 2008-07-09 |
PL223343B1 (pl) | 2016-10-31 |
NO20031498D0 (no) | 2003-04-02 |
EP1330442B1 (en) | 2011-01-19 |
WO2002036576A1 (en) | 2002-05-10 |
GB2384776B (en) | 2004-03-03 |
CY1111380T1 (el) | 2015-08-05 |
KR20030059811A (ko) | 2003-07-10 |
IL155645A (en) | 2008-04-13 |
NO20031498L (no) | 2003-04-02 |
GB0309190D0 (en) | 2003-05-28 |
AU2001295789C1 (en) | 2002-05-15 |
NZ525138A (en) | 2004-03-26 |
EA006300B1 (ru) | 2005-10-27 |
GB2384776C (en) | 2006-02-03 |
AU9578901A (en) | 2002-05-15 |
HUP0301269A2 (hu) | 2003-12-29 |
CA2423279C (en) | 2011-07-05 |
HU228960B1 (hu) | 2013-07-29 |
EP1330442A1 (en) | 2003-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2384776B (en) | Phthalazinone derivatives | |
HK1054042A1 (en) | 2-Aminocarbonyl-9h-purine derivatives | |
HRP20030055A2 (en) | 4-phenyl-pyridine derivatives | |
IL150841A0 (en) | 1h-imidazopyridine derivatives | |
IL154131A0 (en) | Quinazoline derivatives | |
IL155103A0 (en) | Substituted c-cyclohexylmethylamine derivatives | |
IL155106A0 (en) | Substituted 1-aminobutan-3-ol derivatives | |
IL150557A0 (en) | Substituted aminomethyl-phenyl-cyclohexane derivatives | |
HK1052499A1 (zh) | 氨基磺酰基聯苯基衍生物 | |
IL150558A0 (en) | Aminomethyl-phenyl-cyclohexanone derivatives | |
GB0026505D0 (en) | Phthalazinone derivatives | |
AU2163202A (en) | 5-amino-1-pentene-3-ol substituted derivatives | |
IL151598A0 (en) | 2-phenylpyran-4-one derivatives | |
HK1054937A1 (en) | 1-Methylcarbapenem derivatives | |
GB0021639D0 (en) | Maurotoxin derivatives | |
SI1246793T1 (en) | Substituted aminomethyl-phenyl-cyclohexane derivatives | |
SI1322590T1 (sl) | Substituirani 5-amino-1-penten-3-olni derivati | |
GB0015376D0 (en) | Quinazoline derivatives | |
GB0030989D0 (en) | Quinazoline derivatives |